Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.
View Top Employees from Humanigen, Inc.Website | https://www.humanigen.com/ |
Ticker | HGEN |
Revenue | $324000 |
Funding | $78 million |
Employees | 10 (10 on RocketReach) |
Founded | 2001 |
Address | 830 Morris Tpke Fl 4, Short Hills, New Jersey 07078, US |
Phone | (650) 243-3100 |
Technologies |
JavaScript,
HTML,
PHP
+23 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Hospitals & Clinics, Biotechnology, Healthcare, Science and Engineering, Health Care, Pharmaceutical |
Competitors | Biosceptre International Limited, Minerva Neurosciences, Patrys Limited, Precision Biologics, Soligenix, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular Humanigen, Inc. employee's phone or email?
The Humanigen, Inc. annual revenue was $324000 in 2024.
Ken Trbovich is the Senior Vice President of Humanigen, Inc..
10 people are employed at Humanigen, Inc..
Humanigen, Inc. is based in Short Hills, New Jersey.
The NAICS codes for Humanigen, Inc. are [325, 32, 32541, 3254].
The SIC codes for Humanigen, Inc. are [283, 28].